Hormonelle orale Kontrazeption – welches Präparat für welche Patientin? View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2021-09-13

AUTHORS

Thomas Römer

ABSTRACT

Oral contraceptives are mainly used for birth control in Germany. The choice is between a combined oral contraception and a gestagen monotherapy. For combined oral contraception the estrogen component ethinyl estradiol is available in various doses in addition to estradiol. Furthermore, the selection of the optimal gestagen in the combination, plays a particularly important role in the clinical practice. In gestagen monotherapy there is also a choice between desogestrel and drospirenone. In general, the risk of venous thromboembolism is important for the combined oral contraception, whereas for special indications the partial effects of the individual gestagens should be considered in addition to the dosing of ethinyl estradiol. From this there are special advantages for the individual combined oral contraceptives as well as for gestagen monotherapy in different patients. Therefore, patients can benefit not only from a reliable contraception but also in many gynecological diseases from the additional effects of oral contraception. In this article the principles of decision guidance in the practice are presented and practical recommendations are given for 13 special situations based on scientific data. More... »

PAGES

259-267

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10304-021-00412-8

DOI

http://dx.doi.org/10.1007/s10304-021-00412-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1141079233


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Frauenklinik, Evangelisches Klinikum K\u00f6ln-Weyertal, Weyertal\u00a076, 50931, K\u00f6ln, Deutschland", 
          "id": "http://www.grid.ac/institutes/grid.500055.5", 
          "name": [
            "Frauenklinik, Evangelisches Klinikum K\u00f6ln-Weyertal, Weyertal\u00a076, 50931, K\u00f6ln, Deutschland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "R\u00f6mer", 
        "givenName": "Thomas", 
        "id": "sg:person.012355501324.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012355501324.42"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00129-012-3047-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026196794", 
          "https://doi.org/10.1007/s00129-012-3047-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00228-018-2494-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1104329600", 
          "https://doi.org/10.1007/s00228-018-2494-5"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-09-13", 
    "datePublishedReg": "2021-09-13", 
    "description": "Oral contraceptives are mainly used for birth control in Germany. The choice is between a combined oral contraception and a gestagen monotherapy. For combined oral contraception the estrogen component ethinyl estradiol is available in various doses in addition to estradiol. Furthermore, the selection of the optimal gestagen in the combination, plays a particularly important role in the clinical practice. In gestagen monotherapy there is also a choice between desogestrel and drospirenone. In general, the risk of venous thromboembolism is important for the combined oral contraception, whereas for special indications the partial effects of the individual gestagens should be considered in addition to the dosing of ethinyl estradiol. From this there are special advantages for the individual combined oral contraceptives as well as for gestagen monotherapy in different patients. Therefore, patients can benefit not only from a reliable contraception but also in many gynecological diseases from the additional effects of oral contraception. In this article the principles of decision guidance in the practice are presented and practical recommendations are given for 13 special situations based on scientific data.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10304-021-00412-8", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1032804", 
        "issn": [
          "1610-2894", 
          "1610-2908"
        ], 
        "name": "Gyn\u00e4kologische Endokrinologie", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "keywords": [
      "combined oral contraception", 
      "oral contraception", 
      "oral contraceptives", 
      "ethinyl estradiol", 
      "venous thromboembolism", 
      "reliable contraception", 
      "gynecological diseases", 
      "special indications", 
      "clinical practice", 
      "monotherapy", 
      "contraception", 
      "different patients", 
      "estradiol", 
      "patients", 
      "contraceptives", 
      "gestagens", 
      "birth control", 
      "additional effect", 
      "thromboembolism", 
      "desogestrel", 
      "partial effect", 
      "drospirenone", 
      "dosing", 
      "disease", 
      "doses", 
      "Patientin", 
      "important role", 
      "special situations", 
      "risk", 
      "scientific data", 
      "indications", 
      "effect", 
      "practical recommendations", 
      "practice", 
      "addition", 
      "recommendations", 
      "control", 
      "role", 
      "choice", 
      "guidance", 
      "combination", 
      "data", 
      "special advantages", 
      "decision guidance", 
      "Germany", 
      "selection", 
      "article", 
      "situation", 
      "advantages", 
      "principles", 
      "gestagen monotherapy", 
      "estrogen component ethinyl estradiol", 
      "component ethinyl estradiol", 
      "optimal gestagen", 
      "individual gestagens", 
      "Hormonelle orale Kontrazeption", 
      "orale Kontrazeption", 
      "Kontrazeption", 
      "Pr\u00e4parat f\u00fcr welche Patientin", 
      "f\u00fcr welche Patientin", 
      "welche Patientin"
    ], 
    "name": "Hormonelle orale Kontrazeption \u2013 welches Pr\u00e4parat f\u00fcr welche Patientin?", 
    "pagination": "259-267", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1141079233"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10304-021-00412-8"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10304-021-00412-8", 
      "https://app.dimensions.ai/details/publication/pub.1141079233"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T19:02", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_914.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10304-021-00412-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10304-021-00412-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10304-021-00412-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10304-021-00412-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10304-021-00412-8'


 

This table displays all metadata directly associated to this object as RDF triples.

127 TRIPLES      22 PREDICATES      87 URIs      77 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10304-021-00412-8 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N5c44a9da64804a3aa1e7bb21e1b30957
4 schema:citation sg:pub.10.1007/s00129-012-3047-0
5 sg:pub.10.1007/s00228-018-2494-5
6 schema:datePublished 2021-09-13
7 schema:datePublishedReg 2021-09-13
8 schema:description Oral contraceptives are mainly used for birth control in Germany. The choice is between a combined oral contraception and a gestagen monotherapy. For combined oral contraception the estrogen component ethinyl estradiol is available in various doses in addition to estradiol. Furthermore, the selection of the optimal gestagen in the combination, plays a particularly important role in the clinical practice. In gestagen monotherapy there is also a choice between desogestrel and drospirenone. In general, the risk of venous thromboembolism is important for the combined oral contraception, whereas for special indications the partial effects of the individual gestagens should be considered in addition to the dosing of ethinyl estradiol. From this there are special advantages for the individual combined oral contraceptives as well as for gestagen monotherapy in different patients. Therefore, patients can benefit not only from a reliable contraception but also in many gynecological diseases from the additional effects of oral contraception. In this article the principles of decision guidance in the practice are presented and practical recommendations are given for 13 special situations based on scientific data.
9 schema:genre article
10 schema:inLanguage en
11 schema:isAccessibleForFree false
12 schema:isPartOf N8fc71ce0c4c747eb93af2a0ca9f81636
13 N996bd8756edc45438265eaf9a7cd3c02
14 sg:journal.1032804
15 schema:keywords Germany
16 Hormonelle orale Kontrazeption
17 Kontrazeption
18 Patientin
19 Präparat für welche Patientin
20 addition
21 additional effect
22 advantages
23 article
24 birth control
25 choice
26 clinical practice
27 combination
28 combined oral contraception
29 component ethinyl estradiol
30 contraception
31 contraceptives
32 control
33 data
34 decision guidance
35 desogestrel
36 different patients
37 disease
38 doses
39 dosing
40 drospirenone
41 effect
42 estradiol
43 estrogen component ethinyl estradiol
44 ethinyl estradiol
45 für welche Patientin
46 gestagen monotherapy
47 gestagens
48 guidance
49 gynecological diseases
50 important role
51 indications
52 individual gestagens
53 monotherapy
54 optimal gestagen
55 oral contraception
56 oral contraceptives
57 orale Kontrazeption
58 partial effect
59 patients
60 practical recommendations
61 practice
62 principles
63 recommendations
64 reliable contraception
65 risk
66 role
67 scientific data
68 selection
69 situation
70 special advantages
71 special indications
72 special situations
73 thromboembolism
74 venous thromboembolism
75 welche Patientin
76 schema:name Hormonelle orale Kontrazeption – welches Präparat für welche Patientin?
77 schema:pagination 259-267
78 schema:productId N138c742615a144c5805323693313688b
79 N9ff1dd037e3b471ea03c3af6053fbb0f
80 schema:sameAs https://app.dimensions.ai/details/publication/pub.1141079233
81 https://doi.org/10.1007/s10304-021-00412-8
82 schema:sdDatePublished 2022-01-01T19:02
83 schema:sdLicense https://scigraph.springernature.com/explorer/license/
84 schema:sdPublisher Nabb7e144814c414bb6b4b36286b2b783
85 schema:url https://doi.org/10.1007/s10304-021-00412-8
86 sgo:license sg:explorer/license/
87 sgo:sdDataset articles
88 rdf:type schema:ScholarlyArticle
89 N138c742615a144c5805323693313688b schema:name doi
90 schema:value 10.1007/s10304-021-00412-8
91 rdf:type schema:PropertyValue
92 N5c44a9da64804a3aa1e7bb21e1b30957 rdf:first sg:person.012355501324.42
93 rdf:rest rdf:nil
94 N8fc71ce0c4c747eb93af2a0ca9f81636 schema:issueNumber 4
95 rdf:type schema:PublicationIssue
96 N996bd8756edc45438265eaf9a7cd3c02 schema:volumeNumber 19
97 rdf:type schema:PublicationVolume
98 N9ff1dd037e3b471ea03c3af6053fbb0f schema:name dimensions_id
99 schema:value pub.1141079233
100 rdf:type schema:PropertyValue
101 Nabb7e144814c414bb6b4b36286b2b783 schema:name Springer Nature - SN SciGraph project
102 rdf:type schema:Organization
103 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
104 schema:name Medical and Health Sciences
105 rdf:type schema:DefinedTerm
106 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
107 schema:name Clinical Sciences
108 rdf:type schema:DefinedTerm
109 sg:journal.1032804 schema:issn 1610-2894
110 1610-2908
111 schema:name Gynäkologische Endokrinologie
112 schema:publisher Springer Nature
113 rdf:type schema:Periodical
114 sg:person.012355501324.42 schema:affiliation grid-institutes:grid.500055.5
115 schema:familyName Römer
116 schema:givenName Thomas
117 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012355501324.42
118 rdf:type schema:Person
119 sg:pub.10.1007/s00129-012-3047-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026196794
120 https://doi.org/10.1007/s00129-012-3047-0
121 rdf:type schema:CreativeWork
122 sg:pub.10.1007/s00228-018-2494-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104329600
123 https://doi.org/10.1007/s00228-018-2494-5
124 rdf:type schema:CreativeWork
125 grid-institutes:grid.500055.5 schema:alternateName Frauenklinik, Evangelisches Klinikum Köln-Weyertal, Weyertal 76, 50931, Köln, Deutschland
126 schema:name Frauenklinik, Evangelisches Klinikum Köln-Weyertal, Weyertal 76, 50931, Köln, Deutschland
127 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...